At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
ENMD-2076drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Oral ENMD-2076 Administered to Patients With Advanced/Metastatic Soft Tissue Sarcoma
In Brief
A Phase 2 clinical trial evaluating ENMD-2076 for Advanced and 2 related conditions. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This is a phase 2 study of ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma. This study will help to understand how well ENMD-2076 works and how safe and tolerable the drug is in this patient population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced, Metastatic, Soft Tissue Sarcoma
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartJan 2013
Primary CompletionDec 2015
Study CompletionJan 2016
TodayJul 2026
First PostedNov 1, 2012
Enrollment StartJan 1, 2013
Primary CompletionDec 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.7 years ago
Interventions
ENMD-2076drug